TY  - GEN
AU  - Siebels,M
AU  - Rohrmann,K
AU  - Oberneder,R
AU  - Stahler,M
AU  - Haseke,N
AU  - Beck,J
AU  - Hofmann,R
AU  - Kindler,M
AU  - Kloepfer,P
AU  - Stief,C
TI  - A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients
SN  - 1433-8726
PY  - 2011///0524
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antineoplastic Agents
KW  - Carcinoma, Renal Cell
KW  - drug therapy
KW  - Dose-Response Relationship, Drug
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Kidney Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Recombinant Proteins
KW  - Retrospective Studies
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s00345-010-0570-2
ER  -